胃食道逆流症治療市場規模、佔有率和成長分析：按藥物類別、疾病類型、給藥途徑、分銷管道、最終用戶、病患小組和地區分類－2026-2033年產業預測

2024 年全球胃食道逆流症 (GERD) 治療市場價值為 67 億美元，預計從 2025 年的 69.5 億美元成長到 2033 年的 93.7 億美元，預測期（2026-2033 年）的複合年成長率為 3.8%。

胃食道逆流症 (GERD) 治療市場正經歷顯著成長，這主要受 GERD 盛行率上升和診斷可及性提高的推動，從而導致對有效治療方法的持續需求。該市場涵蓋多種治療方法，包括抑制胃酸分泌的處方藥、緩解症狀的非處方藥、外科手術和內視鏡介入治療以及先進的診斷工具。儘管 GERD 治療的經濟負擔沉重，但目前存在一個明顯的趨勢，即擴大依賴質子幫浦阻斷劑(PPI)，尤其是奧美拉唑，同時也在推廣使用一些侵入性較小的治療方法，例如鉀離子競爭性抑酸劑和內鏡下胃底折疊術。治療策略的演變，加上研發投入的增加和診斷能力的提升，反映出治療方向正轉向滿足對傳統 PPI 療法抗藥性患者的未滿足需求。

全球胃食道逆流症 (GERD) 治療市場的成長要素

胃食道逆流症 (GERD) 的日益普遍推動了對有效治療方法的需求成長。隨著越來越多的人尋求緩解 GERD 症狀，醫療專業人員和醫療系統也越來越積極地致力於改進治療方案，這反過來又促進了製藥公司創新研發新治療方法。患者對症狀的認知不斷提高，加上疾病帶來的持續負擔，促使患者對處方治療的依從性更高。這一趨勢不僅推動了治療市場的擴張，也促進了 GERD 管理在基層醫療機構中的進一步整合，最終提高了產品利用率和市場成長。

全球胃食道逆流症（GERD）治療市場面臨的限制因素

由於新型治療方法和給藥系統的成本高於標準藥物，全球胃食道逆流症 (GERD) 治療市場面臨許多限制因素，包括病患就醫管道有限和醫療覆蓋不足。在醫療預算緊張的情況下，公共和私人保險公司越來越重視這些創新治療方法與低成本替代方案相比的額外益處，這往往導致更嚴格的准​​入措施，例如預先核准和分階段報銷。此外，有限的健保覆蓋範圍和高昂的自付費用也引發了人們對經濟負擔的擔憂，阻礙了治療的啟動和持續。這種情況顯著減緩了市場滲透速度，並降低了新治療方法快速商業化的動力。

全球胃食道逆流症（GERD）治療市場趨勢

全球胃食道逆流症 (GERD) 治療市場正日益轉向個人化治療方案，以滿足每位患者的獨特需求。臨床醫師和研發人員正優先考慮患者個人化的管理策略，並充分考慮表現型、症狀模式和合併症等多種因素。這一趨勢強調利用生物標記指導治療決策、促進標靶藥物選擇以及個人化治療方案，從而最大限度地減少不必要的治療。透過開發適應性臨床路徑並促進與患者的共同決策，市場正朝著整合全面的醫療、行為和生活方式介入的方向發展，以全面改善患者的生活品質和治療效果。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球胃食道逆流症 (GERD) 治療藥物市場規模：按藥物類別分類

• 質子幫浦阻斷劑（PPI）
• H2受體拮抗劑
• 制酸劑
• 運動興奮劑
• 鉀競爭性酸分泌抑制劑（P-CABs）
• 其他

全球胃食道逆流症 (GERD) 治療市場規模：依疾病類型分類

• 侵蝕性胃食道逆流症
• 非糜爛性逆流症（NERD）
• 難治性胃食道逆流症
• 伴有巴瑞特氏食道症症

全球胃食道逆流症 (GERD) 治療藥物市場規模：按給藥途徑分類

• 口服
• 注射藥物

全球胃食道逆流症 (GERD) 治療市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球胃食道逆流症 (GERD) 治療市場規模：按最終用戶分類。

• 醫院
• 專科診所
• 居家照護環境

全球胃食道逆流症 (GERD) 治療市場規模：按病患小組分類

• 兒童
• 成人
• 老年人

全球胃食道逆流症 (GERD) 治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer
• Takeda Pharmaceutical Company
• Phathom Pharmaceuticals
• Eisai
• AstraZeneca
• GSK
• Johnson & Johnson
• Bausch Health Companies
• Teva Pharmaceutical Industries
• Dr. Reddy's Laboratories
• Sun Pharmaceutical Industries
• Cipla
• Torrent Pharmaceuticals
• Cadila Pharmaceuticals
• Sandoz
• Viatris
• Daewoong Pharmaceutical
• Yuhan Corporation
• Sebela Pharmaceuticals
• Bayer

結論與建議

Global Gastroesophageal Reflux Disease Therapeutics Market size was valued at USD 6.70 Billion in 2024 and is poised to grow from USD 6.95 Billion in 2025 to USD 9.37 Billion by 2033, growing at a CAGR of 3.8% during the forecast period (2026-2033).

The gastroesophageal reflux disease (GERD) therapeutics market is experiencing significant growth fueled by rising GERD prevalence and enhanced diagnostic accessibility, thus creating a continuous demand for effective treatments. This market encompasses a range of therapies, including prescription medications that inhibit acid secretion, over-the-counter remedies that alleviate symptoms, surgical and endoscopic interventions, and advanced diagnostic tools. Though the economic burden of GERD treatment is substantial, there is a notable trend toward increased reliance on proton pump inhibitors (PPIs), particularly omeprazole, while introducing potassium competitive acid blockers and less invasive options like endoscopic fundoplication. The evolution in treatment strategies, coupled with heightened R&D investments and improved diagnostic capabilities, reflects a shift towards addressing the unmet needs of patients resistant to traditional PPI therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroesophageal Reflux Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastroesophageal Reflux Disease Therapeutics Market Segments Analysis

Global gastroesophageal reflux disease therapeutics market is segmented by drug class, disease type, route of administration, distribution channel, end user, patient group and region. Based on drug class, the market is segmented into proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, prokinetic agents, potassium-competitive acid blockers (P-CABs) and others. Based on disease type, the market is segmented into erosive GERD, non-erosive reflux disease (NERD), refractory GERD and GERD with Barrett's esophagus. Based on route of administration, the market is segmented into oral and injectable. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, specialty clinics and homecare settings. Based on patient group, the market is segmented into pediatric, adult and geriatric. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastroesophageal Reflux Disease Therapeutics Market

The rising incidence of gastroesophageal reflux disease (GERD) is driving an escalating demand for effective treatments. As more individuals seek relief from GERD symptoms, healthcare providers and systems are increasingly motivated to enhance treatment pathways, which in turn encourages pharmaceutical companies to innovate and develop new therapeutic options. Patients' growing awareness of their symptoms, coupled with the persistent burden of the condition, fosters high adherence to prescribed therapies. This dynamic not only expands the treatment market but also facilitates deeper integration of GERD management within primary care settings, thereby boosting overall product utilization and market growth.

Restraints in the Global Gastroesophageal Reflux Disease Therapeutics Market

The Global Gastroesophageal Reflux Disease Therapeutics market faces significant restraints due to the high pricing of new therapies and delivery systems compared to standard medications, which restricts patient access and formulary inclusion. As healthcare budgets tighten, public and private payers increasingly scrutinize the incremental benefits of these innovative treatments against lower-cost alternatives, often leading to stricter access measures such as prior authorization or tiered reimbursement. Additionally, limited insurance coverage and high out-of-pocket costs raise affordability concerns, hindering both the initiation and continuation of treatment. This situation significantly slows market penetration and diminishes the motivation for rapid commercialization of new therapies.

Market Trends of the Global Gastroesophageal Reflux Disease Therapeutics Market

The Global Gastroesophageal Reflux Disease (GERD) Therapeutics market is increasingly witnessing a shift towards personalized treatment approaches that cater to the unique needs of individual patients. Clinicians and developers are prioritizing tailored management strategies by considering various factors such as phenotypes, symptom patterns, and comorbidities. This trend emphasizes the use of biomarkers to guide therapeutic decisions, facilitate the selection of targeted pharmacologic agents, and tailor procedural interventions to minimize unnecessary treatments. By fostering adaptive clinical pathways and promoting shared decision-making, the market is evolving to integrate comprehensive medical, behavioral, and lifestyle interventions that collectively enhance patient quality of life and treatment outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Gastroesophageal Reflux Disease Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Proton Pump Inhibitors (PPIs)
• H2 Receptor Antagonists
• Antacids
• Prokinetic Agents
• Potassium-Competitive Acid Blockers (P-CABs)
• Others

Global Gastroesophageal Reflux Disease Therapeutics Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Erosive GERD
• Non-Erosive Reflux Disease (NERD)
• Refractory GERD
• GERD with Barrett's Esophagus

Global Gastroesophageal Reflux Disease Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Gastroesophageal Reflux Disease Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Gastroesophageal Reflux Disease Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare Settings

Global Gastroesophageal Reflux Disease Therapeutics Market Size by Patient Group & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Gastroesophageal Reflux Disease Therapeutics Market Size & CAGR (2026-2033)

• North America (Drug Class, Disease Type, Route of Administration, Distribution Channel, End User, Patient Group)
  • US
  • Canada
• Europe (Drug Class, Disease Type, Route of Administration, Distribution Channel, End User, Patient Group)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Disease Type, Route of Administration, Distribution Channel, End User, Patient Group)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Disease Type, Route of Administration, Distribution Channel, End User, Patient Group)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Disease Type, Route of Administration, Distribution Channel, End User, Patient Group)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phathom Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daewoong Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yuhan Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sebela Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations